Who are the HIV Vaccine Trials Network (HVTN) and the HIV Prevention Trials Network (HPTN)? The HVTN and HPTN are both international collaborations of scientists, educators, and community members searching for ways to prevent HIV/AIDS. The HVTN focuses on safe and effective vaccines, while the HPTN focuses on other HIV prevention methods such as pre-exposure prophylaxis (PrEP) and treatment as prevention (TasP). We have joined forces to combine our strengths on many current and upcoming studies of broadly neutralizing antibodies (bnAbs) to see if bnAbs will protect people from acquiring HIV. We have clinical trial locations around the world.
Globally, thousands of people acquire HIV daily. In the US, more than 37,000 people acquire HIV every year. Throughout history, vaccines have been one of the most important tools to end infectious diseases. Until a vaccine that can end HIV is available, it is also critical to identify other effective HIV preventive strategies. Join us in our efforts to end HIV.
Our funding is provided by public and private sources; the National Institute of Allergy and Infectious Diseases (NIAID) of the U.S. National Institutes of Health (NIH), an agency of the U.S. Department of Health and Human Services (DHHS), is our main funder and the sponsor of most of our trials. Another signiﬁcant funding source is the Bill & Melinda Gates Foundation. The HVTN is based at Fred Hutchinson Cancer Research Center in Seattle, Washington. The HPTN Leadership and Operations Center is based at FHI 360 in Durham, North Carolina.